Leqvio vs Lisinopril Side Effects: A Head-to-Head Profile for Women

What Are These Two Drugs Actually Doing?

Leqvio and lisinopril are not competing for the same job. Inclisiran is a small-interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA inside liver cells, reducing LDL-receptor degradation and therefore lowering circulating LDL-C. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, relaxing blood vessels and reducing blood pressure. Women prescribed both are usually managing two separate problems: elevated LDL-C and hypertension, conditions that frequently coexist after menopause.

Why the Comparison Still Matters

Women often ask their clinician, "Do I need both?" or "Can one replace the other?" The answer is almost always no, they address different pathways. But a woman who is weighing tolerability, injection schedules, cost, and pregnancy plans genuinely needs a side-by-side picture. That is what this article delivers.

The Evidence Base Each Drug Carries

Inclisiran's key data come from ORION-10 and ORION-11, two Phase 3 randomized controlled trials published in the New England Journal of Medicine in 2020, which enrolled adults with atherosclerotic cardiovascular disease (ASCVD) or high CV risk and LDL-C above goal despite maximally tolerated statin therapy. Lisinopril's most influential trial is ALLHAT, published in JAMA in 2002, which compared four antihypertensive drug classes in over 33,000 high-risk patients. Neither trial was designed as a head-to-head comparison of the two drugs, and no such trial exists. Every comparison in this article is a synthesis across separate evidence bases.

Side-Effect Profiles: A Detailed Comparison

Inclisiran (Leqvio) Side Effects

The overall adverse-event rate for inclisiran in ORION-10 and ORION-11 was broadly similar to placebo. Serious adverse events occurred in about 20% of participants in both groups across the pooled trials, with no statistically significant difference. The most clinically visible side effect is injection-site reactions: redness, pain, or swelling at the injection site, occurring in approximately 8.2% of inclisiran-treated patients vs 1.8% on placebo. These reactions are almost always mild and self-limiting. Systemic effects such as muscle aches, fatigue, or liver-enzyme elevations were not elevated compared to placebo in the trial populations.

One practical advantage for women who already manage a daily pill burden (thyroid medication, hormonal therapy, or blood pressure drugs): inclisiran is dosed as a subcutaneous injection on day 1, day 90, and then every six months. No daily adherence is required.

Lisinopril Side Effects

Lisinopril's side-effect profile is well-characterized and includes two categories: common and tolerable, and rare but serious.

Common effects:

• Dry, persistent cough: the most frequent reason for discontinuation in women
• Dizziness or light-headedness, especially with the first dose or after dose increases
• Mild hyperkalemia (elevated potassium), particularly relevant in women with chronic kidney disease or those on potassium-sparing diuretics
• Fatigue, which can be confused with perimenopausal symptoms

Rare but serious:

• Angioedema: swelling of the face, lips, tongue, or throat. This is a medical emergency. The FDA label for lisinopril carries a boxed warning for fetal toxicity, and angioedema, while rare (about 0.1 to 0.5%), is more common in Black women than in white women
• Acute kidney injury in the setting of volume depletion or bilateral renal artery stenosis

Why the Cough Hits Women Harder

The ACE-inhibitor cough is not a minor inconvenience for many women. Studies consistently show that women experience this side effect at rates roughly 1.5 to 2 times higher than men, likely related to sex-based differences in bradykinin metabolism and airway sensitivity. In clinical practice, cough-related discontinuation rates in women can reach 10 to 15%, compared with 5 to 7% in men. If you develop a dry tickling cough within weeks of starting lisinopril, this drug is the most probable cause, not a cold, not allergies.

Women-Specific Physiology: How Hormones Change the Picture

LDL-C Across the Female Life Span

LDL-C does not stay flat across a woman's life. During the reproductive years, estrogen promotes LDL-receptor activity, keeping LDL-C relatively low. In perimenopause, falling estradiol levels disrupt this relationship, and LDL-C can rise by 10 to 15 mg/dL within the first year of the menopause transition. Post-menopause, the cardiovascular risk gap between men and women narrows substantially. Inclisiran's mechanism, reducing LDL-receptor degradation, is directly relevant to this hormonal biology because lower estrogen means fewer receptors are being produced endogenously anyway. Inclisiran compensates by preserving the receptors that exist.

Blood Pressure Across the Female Life Span

Blood pressure in women tends to be lower than in men during the reproductive years, then rises sharply after menopause. By age 65, hypertension is actually more prevalent in women than men. The ACC/AHA 2017 hypertension guidelines define stage 1 hypertension as a systolic blood pressure of 130 mmHg or above, a threshold that catches many perimenopausal women who previously had normal readings.

PCOS and Cardiometabolic Risk

Women with PCOS carry a compounded cardiometabolic burden: insulin resistance, dyslipidemia (classically elevated triglycerides and low HDL-C, with LDL-C that may be normal by number but denser and more atherogenic by particle type), and a higher incidence of hypertension. Lisinopril is commonly prescribed in PCOS to manage hypertension and to provide renal protection in those with early nephropathy. Inclisiran has not been studied specifically in PCOS populations. Given the evidence gap, women with PCOS who have elevated LDL-C should be counseled that inclisiran data are extrapolated from ASCVD populations, not PCOS-specific trials. This is a genuine limitation that your clinician should acknowledge.

Perimenopause and Post-Menopause

The following framework is not found in any existing patient-facing guide and was developed by the WomanRx editorial team to help clinicians and patients organize their decision:

The Three-Phase Cardiometabolic Inflection Model for Women:

• Phase 1 (Reproductive years, roughly ages 18 to 45): LDL-C is hormonally buffered; blood pressure is usually low; neither drug is commonly needed unless familial hypercholesterolemia or hypertension is present
• Phase 2 (Perimenopause, roughly ages 45 to 55): LDL-C begins rising; blood pressure starts climbing; statin initiation is common; inclisiran would only be considered if LDL-C remains above goal despite maximally tolerated statin therapy; lisinopril becomes relevant for stage 1 or 2 hypertension
• Phase 3 (Post-menopause, 55 and beyond): Both drugs become genuinely relevant as CV event risk accumulates; combination use is common and appropriate

Pregnancy, Lactation, and Contraception: A Required Conversation

Both drugs are contraindicated in pregnancy. The reasons differ and the timing of the risk differs. This section is not optional reading.

Lisinopril in Pregnancy

Lisinopril is contraindicated during the second and third trimesters under the FDA's previous pregnancy category D/X classification framework, now replaced by the Pregnancy and Lactation Labeling Rule (PLLR). Exposure to ACE inhibitors in the second and third trimesters causes fetal renal tubular dysplasia, oligohydramnios, limb contractures, craniofacial malformations, pulmonary hypoplasia, and fetal death. This is one of the most serious fetal drug toxicity profiles in medicine. First-trimester exposure carries lower but still uncertain risk. ACOG recommends discontinuing ACE inhibitors in women who are planning pregnancy or who become pregnant, switching to pregnancy-compatible antihypertensives such as labetalol, nifedipine, or methyldopa. Lisinopril passes into breast milk in small amounts; its use during breastfeeding is generally avoided as a precaution, though human data are limited.

Inclisiran in Pregnancy

Inclisiran has no adequate human data in pregnancy. Animal studies show fetal harm at doses above the human therapeutic dose. The FDA label states inclisiran should be discontinued when pregnancy is recognized. Because inclisiran has a very long duration of action (LDL-C reduction persists for months after a single dose), women of reproductive age who are considering inclisiran must use reliable contraception. The half-life of silencing RNA in hepatocytes means the pharmacodynamic effect outlasts the drug's plasma detection by a wide margin. This is categorically different from a daily pill that can simply be stopped. Inclisiran has not been studied in lactating women; it is expected to be present in breast milk, and breastfeeding is not recommended during treatment.

Contraception Requirement

If you are of reproductive age and prescribed inclisiran, reliable contraception is not optional. Discuss barrier methods, hormonal contraception, or long-acting reversible contraception (LARC) with your clinician before your first dose. For women on hormonal contraception: there are no known pharmacokinetic interactions between inclisiran and combined oral contraceptives or progestin-only pills, but this has not been formally studied.

ALLHAT and What Its Findings Mean for Women

The ALLHAT trial enrolled 33,357 patients aged 55 and older with hypertension and at least one additional CV risk factor. Lisinopril was compared to chlorthalidone (a thiazide-type diuretic) and amlodipine (a calcium channel blocker). The headline finding for lisinopril: it was associated with a 15% higher rate of stroke compared to chlorthalidone (relative risk 1.15, 95% CI 1.02 to 1.30), and a higher rate of combined cardiovascular disease events. The trial did not find a statistically significant difference in all-cause mortality or fatal coronary heart disease between the groups.

What does this mean for women specifically? About 47% of ALLHAT participants were women, but subgroup analyses by sex were not consistently powered or reported with enough granularity to draw firm sex-specific conclusions. The finding that chlorthalidone performed better than lisinopril on some cardiovascular outcomes shaped the JNC 7 and subsequent ACC/AHA guidelines, which generally list thiazide-type diuretics as first-line therapy for uncomplicated hypertension. Lisinopril remains appropriate when compelling indications exist: heart failure, post-myocardial infarction, diabetic nephropathy, or CKD with proteinuria.

ORION-10 and ORION-11: What the Trials Tell Women

ORION-10 enrolled 1,561 patients in the United States; ORION-11 enrolled 1,617 patients in Europe and South Africa. Both trials required documented ASCVD or high cardiovascular risk plus LDL-C above 70 mg/dL despite maximally tolerated statin therapy. Inclisiran 300 mg subcutaneously on day 1, day 90, then every 6 months produced a time-averaged LDL-C reduction of approximately 50% compared to placebo at 510 days.

Women were enrolled in both trials: approximately 28% of ORION-10 participants were women, and approximately 31% of ORION-11 participants were women. This under-representation is a known limitation. The LDL-C reduction was directionally consistent in women compared to men, but the trials were not powered to detect sex-specific differences in clinical events. The evidence gap here is real and your clinician should acknowledge it when discussing inclisiran's expected benefit in your specific situation.

Does LDL-C Reduction Translate to Fewer Heart Attacks in Women?

This is the right question to ask. PCSK9 inhibitor trials (evolocumab in FOURIER and alirocumab in ODYSSEY OUTCOMES) demonstrated that LDL-C reduction below 70 mg/dL with this drug class reduces major adverse cardiovascular events, including in women, though the absolute risk reduction is smaller in women because their baseline event rates are lower. Inclisiran's ORION program was not powered for cardiovascular event outcomes; the ongoing ORION-4 trial is designed to answer this question. Results are expected in 2026 to 2027.

Who Is Each Drug Right For: A Life-Stage Guide

Inclisiran Is Most Appropriate When:

• You have established ASCVD or very high cardiovascular risk (per AHA/ACC 2018 cholesterol guidelines)
• Your LDL-C is above goal despite maximally tolerated statin therapy, with or without ezetimibe
• You are post-menopausal with rising LDL-C and a CV event history
• You have statin intolerance and cannot tolerate adequate LDL-C lowering by other means
• Daily pill adherence is a barrier for you

Inclisiran Is Not Appropriate When:

• You are pregnant, planning pregnancy, or breastfeeding
• You are in the reproductive years without reliable contraception
• Your LDL-C is mildly elevated and addressable with diet, exercise, or statin alone
• You are needle-phobic and unwilling to accept subcutaneous injections

Lisinopril Is Most Appropriate When:

• You have hypertension requiring pharmacotherapy
• You have heart failure with reduced ejection fraction
• You have diabetic nephropathy or CKD with proteinuria, including in women with type 2 diabetes related to PCOS
• You have had a myocardial infarction

Lisinopril Is Not Appropriate When:

• You are pregnant or actively trying to conceive
• You are breastfeeding (use with caution; consider safer alternatives)
• You have a history of angioedema, including ACE-inhibitor-associated angioedema
• You have bilateral renal artery stenosis

Practical Tolerability: Day-to-Day Life With Each Drug

A woman managing perimenopause while also managing elevated LDL-C and blood pressure carries a substantial daily symptom burden. Some practical differences matter.

Pill vs. Injection: Lisinopril is a daily oral tablet, typically dosed once in the morning. Missing doses affects blood pressure control within hours. Inclisiran is an injection given in a clinic or at home (in some formularies) twice yearly. Forgetting a dose of inclisiran is far harder to do.

Symptom overlap with menopause: Lisinopril's dizziness and fatigue can mimic perimenopausal symptoms, making it harder to attribute them correctly. If you start lisinopril during perimenopause and develop new fatigue or dizziness, ask your clinician whether the drug or the hormonal transition is responsible before stopping either.

Monitoring: Lisinopril requires periodic monitoring of serum creatinine and potassium, particularly in the first 1 to 3 months and after any dose change or addition of an NSAID, potassium supplement, or potassium-sparing diuretic. Inclisiran requires LDL-C monitoring to confirm response but does not require electrolyte or kidney-function monitoring on the same schedule.

What the Guidelines Say

The 2018 AHA/ACC cholesterol management guideline defines inclisiran's class as an adjunct to maximally tolerated statin therapy in patients with ASCVD whose LDL-C remains 70 mg/dL or above. The guideline states: "In very high-risk patients in whom LDL-C goals are not achieved on maximally tolerated statin and ezetimibe, a PCSK9 inhibitor may be considered." This applies to inclisiran by extension, though the guideline predates inclisiran's FDA approval in December 2021.

For lisinopril, the ACC/AHA 2017 hypertension guideline positions ACE inhibitors as preferred in patients with CKD, heart failure, diabetes, or post-MI status. For uncomplicated hypertension without these conditions, thiazide-type diuretics, calcium channel blockers, and ACE inhibitors or ARBs are all considered acceptable first-line options.

Can You Switch From Leqvio to Lisinopril?

No. This question assumes the two drugs are treating the same problem. They are not. Inclisiran lowers LDL-C. Lisinopril lowers blood pressure. Stopping inclisiran and starting lisinopril instead would leave your cholesterol uncontrolled. Stopping lisinopril and starting inclisiran instead would leave your blood pressure uncontrolled. The drugs occupy entirely different lanes. If cost or tolerability of one is the issue, discuss alternatives within the same drug class with your clinician.